For the millions who have turned to GLP-1 receptor agonists like Ozempic to manage weight or diabetes, the path forward is rarely as simple as deciding to stop. Medical experts are now drawing attention to a quiet but serious truth: discontinuing these powerful medications without guidance can unravel months of progress and introduce new dangers — metabolic disruption, cardiovascular vulnerability, and the swift return of conditions the drugs had held at bay. The end of a treatment, it turns out, is as consequential as its beginning.